Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for treatment of non-affective psychosis and cannabis use
2018-004893-84Phase 2Active
- Sponsor
- Mental Health Center Glostrup
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of cannabidiol in schizophrenia, paranoid personality disorder (PPD), brief psychotic disorder (BPD) and 4 more, sponsored by Mental Health Center Glostrup. Primary endpoint: PANSS positive subscale score. Started May 2019; status: active.
02
Drugs
cannabidiol
03
Conditions
schizophreniaparanoid personality disorder (PPD)brief psychotic disorder (BPD)schizoaffective disorderSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2018-004893-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004893-84.